MedPath

Wearable 2-week ECG to detect atrial fibrillatio

Phase 3
Conditions
Atrial fibrillation
Registration Number
JPRN-jRCTs032180018
Lead Sponsor
Machino Takeshi
Brief Summary

Wearable 2-week ECG unveiled AF recurrence, which was underdiagnosed with a Holter 24-hour ECG. A 2-week monitoring period overcame the deteriorated acquisition rate of wearable ECG for unveiling the hidden AF recurrence on Holter 24-hour ECG.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
67
Inclusion Criteria

Patients who underwent an initial catheter ablation for atrial fibrillation

Exclusion Criteria

1) Allergies
2) Very sensitive skin to adhesive tape with a history of redness, erosion and scar
3) Cardiac implantable electronic devices

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath